Varicose vein treatment patent case heads to trial
This article was originally published in The Gray Sheet
Executive Summary
VNUS Medical Technologies' patent infringement case against competitors Diomed, AngioDynamics and Vascular Solutions is scheduled to go to trial Oct. 29 in the U.S. District Court in Northern California following the judge's denial of both sides' motions for summary judgment Oct. 2. VNUS, maker of the ClosureFAST radiofrequency system for treatment of varicose veins, alleged infringement of patents related to the technology in 2005. AngioDynamics replaced its VenaCure product with a modified NeverTouch VenaCure system in June after losing a separate patent suit to Diomed, maker of the EVLT endovenous laser treatment. Vascular Solutions also modified its Vari-Lase system as a result of that case (1"The Gray Sheet" April 16, 2007, p. 16)
You may also be interested in...
Vnus endovenous laser ablation settlement
AngioDynamics and Vascular Solutions gain non-exclusive licenses to Vnus Medical patents relating to disposable endovenous laser fiber kits, laser fibers and lasers used for endovenous laser ablation, in exchange for upfront payments of $6.8 million and $3.1 million, respectively, under a settlement of 2005 patent litigation, announced June 3. The license also requires ongoing royalty payments until September 2017 ("1The Gray Sheet" Oct. 8, 2007, In Brief)
Angiodynamics Looks To Overcome Legal Woes, Regain Momentum
Angiodynamics' plan to sidestep patent infringement concerns relating to its VenaCure laser system for varicose veins could help boost sales growth and lift the cloud over the firm's stock performance after a poor showing in the first quarter
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.